title: Targeting oncogenic and epigenetic survival pathways in lymphoma.
abstract: In recent years, several genetic and epigenetic alterations have been identified and linked with deregulated signaling pathways that promote growth and survival of lymphoma cells. These discoveries have raised hopes that a new era of targeted therapy will eventually improve treatment outcome of lymphoma. In this focused review, we summarize emerging preclinical and clinical data supporting the development of novel agents targeting B cell receptor signaling, phosphoinositol-3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) and Janus kinase/signal transducer and activator of transcription (JAK/STAT) oncogenic pathways. Furthermore, we discuss new data on targeting chromatin modulating mechanisms.
authors: Division of Cancer Medicine, M. D. Anderson Cancer Center , Houston, TX , USA.
authors: Lori A
authors: LA
authors: Leslie
authors: Anas
authors: A
authors: Younes
mesh_terms: D000818:Animals; D044127:Epigenesis, Genetic; D006801:Humans; D008223:Lymphoma / Q000235:genetics* / Q000378:metabolism*; D015513:Oncogene Proteins / Q000235:genetics* / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
chemical_list: D015513:Oncogene Proteins; D019869:Phosphatidylinositol 3-Kinases; D011947:Receptors, Antigen, B-Cell; D058570:TOR Serine-Threonine Kinases